CFO
PTCT icon

CVA Family Office’s PTC Therapeutics PTCT Stock Holding History

CVA Family Office’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.59K Buy
93
+13
+16% +$939 ﹤0.01% 1111
2026
Q1 		$5.45K Buy
80
+63
+371% +$4.46K ﹤0.01% 1205
2025
Q4 		$1.29K Hold
17
– – ﹤0.01% 1056
2025
Q3 		$1.04K Hold
17
– – ﹤0.01% 1122
2025
Q2 		$830 Hold
17
– – ﹤0.01% 1128
2025
Q1 		$866 Hold
17
– – ﹤0.01% 1141
2024
Q4 		$767 Hold
17
– – ﹤0.01% 1137
2024
Q3 		$631 Hold
17
– – ﹤0.01% 1146
2024
Q2 		$520 Buy
+17
New +$551 ﹤0.01% 1190

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

CVA Family Office's PTCT Position: Q2 2026 in Review

CVA Family Office increased its PTC Therapeutics (PTCT) stake by 16% in Q2 2026, buying an estimated $939 and bringing the position to 93 shares worth $7.59K. The position accounts for ﹤0.01% of the portfolio, ranked #1111.

CVA Family Office first reported a position in PTCT in Q2 2024 and has held it in 9 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • CVA Family Office held 93 shares of PTC Therapeutics worth $7.59K as of Q2 2026.
  • CVA Family Office bought 13 PTC Therapeutics shares in Q2 2026, an estimated $939.
  • PTC Therapeutics made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1111 holding.
  • CVA Family Office first reported a position in PTC Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.